Voranigo (vorasidenib) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies